Cabot (NYSE:CBT) Stock Price Up 6.7% – Should You Buy?

Shares of Cabot Corporation (NYSE:CBT) rose 6.7% on Thursday . The company traded as high as $92.90 and last traded at $93.3770. Approximately 16,907 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 464,908 shares. The stock had previously closed at $87.49.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CBT. Wall Street Zen raised shares of Cabot from a “hold” rating to a “buy” rating in a research note on Sunday, June 14th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Cabot in a research note on Tuesday, May 26th. Truist Financial started coverage on shares of Cabot in a report on Monday, June 8th. They set a “buy” rating and a $98.00 price objective for the company. Mizuho boosted their price objective on shares of Cabot from $80.00 to $90.00 and gave the company a “neutral” rating in a research report on Thursday. Finally, JPMorgan Chase & Co. upped their target price on shares of Cabot from $68.00 to $70.00 and gave the stock an “underweight” rating in a research note on Wednesday, May 13th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $85.80.

Cabot Stock Performance

The firm has a 50 day moving average price of $82.44 and a 200 day moving average price of $75.41. The stock has a market cap of $4.80 billion, a PE ratio of 17.58, a price-to-earnings-growth ratio of 11.51 and a beta of 0.82. The company has a quick ratio of 0.96, a current ratio of 1.45 and a debt-to-equity ratio of 0.51.

Cabot (NYSE:CBT) last issued its earnings results on Tuesday, May 5th. The specialty chemicals company reported $1.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.14. Cabot had a net margin of 7.97% and a return on equity of 21.33%. The company had revenue of $904.00 million for the quarter, compared to analysts’ expectations of $900.30 million. During the same period in the prior year, the business earned $1.90 EPS. The firm’s quarterly revenue was down 3.4% on a year-over-year basis. Cabot has set its FY 2026 guidance at 6.000-6.50 EPS. As a group, research analysts forecast that Cabot Corporation will post 6.34 earnings per share for the current year.

Cabot Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 29th were issued a dividend of $0.4725 per share. The ex-dividend date of this dividend was Friday, May 29th. This is a positive change from Cabot’s previous quarterly dividend of $0.45. This represents a $1.89 annualized dividend and a yield of 2.0%. Cabot’s dividend payout ratio is 35.73%.

Institutional Trading of Cabot

A number of hedge funds have recently bought and sold shares of the stock. NewEdge Advisors LLC increased its holdings in shares of Cabot by 2,559.5% in the 1st quarter. NewEdge Advisors LLC now owns 984 shares of the specialty chemicals company’s stock valued at $82,000 after acquiring an additional 947 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Cabot by 32.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 442,646 shares of the specialty chemicals company’s stock worth $36,802,000 after purchasing an additional 108,645 shares during the last quarter. Empowered Funds LLC boosted its position in Cabot by 102.6% during the first quarter. Empowered Funds LLC now owns 28,162 shares of the specialty chemicals company’s stock valued at $2,341,000 after purchasing an additional 14,260 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Cabot by 3.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 122,022 shares of the specialty chemicals company’s stock valued at $10,145,000 after purchasing an additional 4,048 shares during the last quarter. Finally, Geneos Wealth Management Inc. grew its stake in Cabot by 409.0% in the first quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock valued at $38,000 after purchasing an additional 364 shares during the last quarter. Hedge funds and other institutional investors own 93.18% of the company’s stock.

Cabot Company Profile

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.